RU2022114084A - ARYL, HETEROARYL AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS - Google Patents
ARYL, HETEROARYL AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS Download PDFInfo
- Publication number
- RU2022114084A RU2022114084A RU2022114084A RU2022114084A RU2022114084A RU 2022114084 A RU2022114084 A RU 2022114084A RU 2022114084 A RU2022114084 A RU 2022114084A RU 2022114084 A RU2022114084 A RU 2022114084A RU 2022114084 A RU2022114084 A RU 2022114084A
- Authority
- RU
- Russia
- Prior art keywords
- disorder
- disease
- pharmaceutically acceptable
- acceptable salt
- compound
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title claims 29
- 150000001875 compounds Chemical class 0.000 title claims 17
- 101700018994 ARYL Proteins 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 10
- 239000011780 sodium chloride Substances 0.000 claims 10
- 206010064930 Age-related macular degeneration Diseases 0.000 claims 6
- 208000002780 Macular Degeneration Diseases 0.000 claims 4
- 206010018364 Glomerulonephritis Diseases 0.000 claims 3
- 101700037337 PIGA Proteins 0.000 claims 3
- 102100012341 PIGA Human genes 0.000 claims 3
- 201000001066 hemolytic-uremic syndrome Diseases 0.000 claims 3
- 230000001404 mediated Effects 0.000 claims 3
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims 3
- 206010003246 Arthritis Diseases 0.000 claims 2
- 208000008787 Cardiovascular Disease Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 102000003706 Complement Factor D Human genes 0.000 claims 2
- 108090000059 Complement Factor D Proteins 0.000 claims 2
- 208000008069 Geographic Atrophy Diseases 0.000 claims 2
- 208000010159 IGA Glomerulonephritis Diseases 0.000 claims 2
- 206010021263 IgA nephropathy Diseases 0.000 claims 2
- 208000005777 Lupus Nephritis Diseases 0.000 claims 2
- 206010028417 Myasthenia gravis Diseases 0.000 claims 2
- 206010053219 Non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 206010038683 Respiratory disease Diseases 0.000 claims 2
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 2
- 208000007056 Sickle Cell Anemia Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 230000024924 glomerular filtration Effects 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 201000007737 retinal degeneration Diseases 0.000 claims 2
- 230000004258 retinal degeneration Effects 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 206010001897 Alzheimer's disease Diseases 0.000 claims 1
- 206010002026 Amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 108090000866 Antiphospholipid Antibodies Proteins 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 208000006673 Asthma Diseases 0.000 claims 1
- 208000000594 Bullous Pemphigoid Diseases 0.000 claims 1
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 claims 1
- 206010009887 Colitis Diseases 0.000 claims 1
- 206010070976 Craniocerebral injury Diseases 0.000 claims 1
- 206010011401 Crohn's disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 208000004930 Fatty Liver Diseases 0.000 claims 1
- 206010018370 Glomerulonephritis membranoproliferative Diseases 0.000 claims 1
- 206010018651 Graft versus host disease Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000007475 Hemolytic Anemia Diseases 0.000 claims 1
- 206010019663 Hepatic failure Diseases 0.000 claims 1
- 206010019708 Hepatic steatosis Diseases 0.000 claims 1
- 208000002557 Hidradenitis Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 210000004185 Liver Anatomy 0.000 claims 1
- 208000007903 Liver Failure Diseases 0.000 claims 1
- 208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 claims 1
- 206010065579 Multifocal motor neuropathy Diseases 0.000 claims 1
- 208000003926 Myelitis Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010034277 Pemphigoid Diseases 0.000 claims 1
- 208000008469 Peptic Ulcer Diseases 0.000 claims 1
- 206010038848 Retinal detachment Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 108010079723 Shiga Toxin Proteins 0.000 claims 1
- 208000008513 Spinal Cord Injury Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 208000005765 Traumatic Brain Injury Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 230000000931 anti-neutrophil Effects 0.000 claims 1
- 108090001123 antibodies Proteins 0.000 claims 1
- 102000004965 antibodies Human genes 0.000 claims 1
- 230000001086 cytosolic Effects 0.000 claims 1
- 201000004624 dermatitis Diseases 0.000 claims 1
- 231100000406 dermatitis Toxicity 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 claims 1
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 230000000302 ischemic Effects 0.000 claims 1
- 201000004044 liver cirrhosis Diseases 0.000 claims 1
- 231100000835 liver failure Toxicity 0.000 claims 1
- 201000011152 pemphigus Diseases 0.000 claims 1
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 1
- 201000011461 pre-eclampsia Diseases 0.000 claims 1
- 230000004264 retinal detachment Effects 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 201000010874 syndrome Diseases 0.000 claims 1
Claims (46)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62/465,782 | 2017-03-01 | ||
US62/466,301 | 2017-03-02 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2019130019A Division RU2773030C2 (en) | 2017-03-01 | 2018-03-01 | Aryl, heteroaryl and heterocyclic pharmaceutical compounds for treatment of medical disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2022114084A true RU2022114084A (en) | 2022-06-03 |
RU2801278C2 RU2801278C2 (en) | 2023-08-07 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2020514331A5 (en) | ||
JP2014520784A5 (en) | ||
EP2824111A3 (en) | Anti-C5A Antibodies and Methods for Using the Antibodies | |
HRP20210472T1 (en) | Bicyclic-fused heteroaryl or aryl compounds as irak4 modulators | |
WO2012109590A3 (en) | Microporous zirconium silicate for the treatment of hyperkalemia | |
JP2016147858A5 (en) | ||
JP2016503010A5 (en) | ||
RU2011135422A (en) | HUMAN ANTI-IL-6 ANTIBODIES WITH A LONG-TERM REDUCED PERIOD OF IN VIVO AND THEIR APPLICATION FOR TREATMENT OF ONCOLOGICAL, AUTOIMMUNE DISEASES AND INFLAMMATORY DISEASES | |
JP2015505564A5 (en) | ||
JP2012521994A5 (en) | ||
RU2018125515A (en) | ANTIBODY AGAINST C5 AND METHOD FOR PREVENTING AND TREATING COMPLEMENTAL DISEASES | |
JP2020105186A5 (en) | ||
JP2020502047A5 (en) | ||
PH12018500533A1 (en) | Pyrazolyl-substituted heteroaryls and their use as medicaments | |
MX2016005955A (en) | Microporous zirconium silicate for the treatment of hyperkalemia. | |
JP2015515976A5 (en) | ||
JP2017512838A5 (en) | ||
JP2016540749A5 (en) | ||
RU2022114084A (en) | ARYL, HETEROARYL AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS | |
JP2016501219A5 (en) | ||
JP2016514710A5 (en) | ||
CA2516514A1 (en) | Arylvinylazacycloalkane compounds and methods of preparation and use thereof | |
RU2017145086A (en) | DERIVATIVES 3- (6-HLOR-3-OXO-3,4-DIHYDRO- (2H) -1,4-BENZOXAZIN-4-IL) PROPIONIC ACID AND THEIR APPLICATION AS KMO INHIBITORS | |
JP2011519950A5 (en) | ||
JP2019535788A5 (en) |